Rocuronium: Supply issue resolved
Some DHBs have advised PHARMAC and Medsafe about a potential lack of efficacy of batch 11331219A of the Hameln brand of rocuronium.
This brand of rocuronium is listed in the Pharmaceutical Schedule and has Hospital Supply Status (HSS) from August 2020 to 2022. Rocuronium is used in anaesthesia to help with intubation.
Medsafe responsible for safety and efficacy
Medsafe are monitoring the situation and working with the supplier, Max Health.
What hospitals can do
Please report any and all events to Medsafe. They need detailed information to investigate any issue.
- Rocuronium Data collection form from Max Health 2020 [PDF 329 KB]
Email the form to:
Hospitals are able to procure alternative rocuronium within the discretionary variance (DV) limit.
What PHARMAC is doing
PHARMAC is engaging with the supplier and Medsafe. We will communicate further as the situation evolves.
If the situation develops to the point that supply of the Hameln brand is interrupted, we understand there is sufficient stock of the DBL brand of rocuronium in New Zealand to maintain continuity of supply.
Who to contact
If you have issues with the efficacy of the Hameln brand of rocuronium, email the information form to:
If you have questions about supply, email firstname.lastname@example.org